Drug intelligence / Profile preview

BCD-263

Development stage: Phase 3
Lead developer: Biocad
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BCD-263 is an intravenously administered biosimilar of nivolumab developed by Biocad for the treatment of advanced melanoma. It is a monoclonal antibody that targets programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor. By blocking PD-1, it enhances the immune system's ability to recognize and destroy cancer cells. The drug is currently in phase 3 clinical trials for use as monotherapy in patients with unresectable or metastatic melanoma[1][2][3][9].

Other names: Nivolumab biosimilar

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on BCD-263.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCD-263.

Explore the full profile